Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched Buprenorphine and Naloxone Sublingual Tablets CIII in 2mg/0.
Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today provided an update on the company’s ongoing restatement process as well as a business …
Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, today announced that Duane A.
Akorn, Inc. (NASDAQ:AKRX), a leading specialty pharmaceutical company, today announced that it has launched Promethazine Hydrochloride and Phenylephrine Hydrochloride Syrup (Promethazine/Phenylephrine) and Promethazine Hydrochloride, …
Akorn, Inc. (NASDAQ:AKRX) announced the appointment ofRandall Pollard as Chief Accounting Officer and Interim Chief Financial Officer.
Akorn, Inc. (NASDAQ:AKRX) dropped 22% yesterday after announcing the discovery of additional errors related to Hi-Tech products during the first-quarter accounting process, which will delay …
Akorn, Inc. (NASDAQ:AKRX) announced on Friday that it will have to restate financials from 2014 due to accounting errors.